India Semaglutide Prices Expected to Drop 70% as 50+ Generics Enter Market
Following Novo Nordisk's patent expiry on March 20, more than 50 generic semaglutide versions are anticipated in India, dramatically expanding GLP-1 access.
#Semaglutide
87 stories
Semaglutide is the active ingredient in Ozempic and Wegovy. Novo Nordisk holds the patent in most markets through 2031, but the Indian patent expired in March 2026 and a wave of generics from Biocon, Dr. Reddy's, and others followed within weeks.
The cardiovascular and renal evidence has expanded fastest. SELECT showed a 20% reduction in MACE for non-diabetic adults with obesity. The REMODEL trial (presented at the World Congress of Nephrology 2026) showed direct kidney protection independent of weight loss. Cell Metabolism work from Sinai Health pinned MASH reversal to liver sinusoidal endothelial cells, not weight loss or appetite. JAMA published a 90,000-patient HFpEF analysis showing a 42% reduction in heart-failure hospitalization or all-cause mortality.
The compounding story keeps moving in parallel. The FDA proposed excluding semaglutide from the 503B bulks list on April 30, 2026, with public comment open through June 29. Tirzepatide and liraglutide were folded into the same proposal.
GLP-1 Medications Show Promise for Treating Addiction in 600,000+ Veteran Study
A BMJ-published study of over 600,000 US veterans found GLP-1 medications tied to reduced risk of substance use disorders across all major addictive substances, plus reduced overdose and death risk.
GLP-1 Medications Increase Testosterone Levels in Men With Obesity
New research shows semaglutide, dulaglutide, and tirzepatide can increase testosterone levels in men with obesity, adding another ancillary benefit to the GLP-1 portfolio.
India Semaglutide Trademark Disputes: Dr. Reddy's Renames Drug After Court Concerns
Dr. Reddy's will rename its semaglutide drug from 'Olymviq' to 'Olymra' after Delhi High Court flagged similarity to Novo Nordisk's 'Ozempic'. Fierce competition in India's generic market.
Washington Post: Comprehensive Guide to GLP-1 Drug Effects on the Body
A condition-by-condition guide examining what's proven, promising, and untested for GLP-1 drugs beyond weight loss — covering cardiovascular disease, addiction, kidney disease, and neurological conditions.
Biocon Skips India's Crowded Generic Semaglutide Market, Eyes Global Expansion
Biocon's incoming CEO said the company will prioritize Canada, Brazil, and the Middle East instead of India's saturated GLP-1 market with 40+ generic entrants.
Eli Lilly and Novo Nordisk Strike MFN Deals to Lower GLP-1 Prices
Both pharma giants reached most-favored-nation pricing agreements with the Trump Administration to reduce costs of tirzepatide and semaglutide for American consumers.
Orforglipron Outperforms Oral Semaglutide in Phase 3 ACHIEVE-3 Trial
Eli Lilly's oral orforglipron demonstrated superior HbA1c reduction and weight loss vs oral semaglutide in Phase 3, strengthening the case ahead of an April FDA decision.
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular and Stroke Benefits
The European Medicines Agency formally approved semaglutide with cardiovascular and stroke-related benefits — a first for any GLP-1 receptor agonist in Europe.
Experts Propose 10-Year Trial to Test GLP-1 Drugs for Cancer Prevention
A panel of 21 obesity and cancer experts proposed a 5,000-participant, decade-long trial to test whether semaglutide and tirzepatide can prevent obesity-related cancers.
FDA Approves Higher 2 mg Dose of Ozempic for Type 2 Diabetes
The FDA approved a new 2 mg dose of Ozempic (semaglutide) injection, providing an additional option for patients needing more intensive glycemic management.
Semaglutide Linked to 42% Drop in Psychiatric Hospital Visits
Large-scale study from University of Eastern Finland and Karolinska Institutet found GLP-1 medications associated with 42% drop in psychiatric hospital visits, 44% lower depression risk, and 47% reduced substance use disorders.
Compounded GLP-1 Prescriptions Keep Rising Despite FDA Crackdown
Healthcare Brew reports that despite the FDA sending thousands of warning letters since September 2025, compounded semaglutide and tirzepatide prescriptions have increased since the semaglutide shortage ended in February 2025. About 80% of compounded GLP-1 prescriptions now include supplemental ingredients like B vitamins to avoid being classified as exact copies of FDA-approved drugs.
Cleveland Clinic Study: Most Patients Avoid Dramatic Weight Regain After Stopping GLP-1 Drugs
A Cleveland Clinic analysis of 7,938 adults who discontinued semaglutide or tirzepatide found that real-world outcomes are better than clinical trials suggested. Obesity patients regained just 0.5% of body weight on average after one year, and 45% either maintained or continued losing weight by restarting treatment, switching medications, or adopting lifestyle changes.
GLP-1 Lawsuits Surpass 3,500 Pending Cases as Vision Loss Claims Surge
Over 3,546 lawsuits are now consolidated in two federal MDLs — one for gastroparesis and one for NAION vision loss. On March 3, a federal judge appointed lead counsel for the NAION MDL. Studies show semaglutide users face a fourfold increase in NAION risk, with vision loss claims now generating more legal attention than earlier gastroparesis cases.